Patents Examined by Daniel R Carcanague
  • Patent number: 11149021
    Abstract: An N-(azaaryl)cyclolactam-1-carboxamide derivative having a structure of formula (I), a preparation method therefor, and a use thereof are disclosed in the application. Each substituent are defined in the specification and claims. The series of compounds of the application can be widely applied in the preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, particularly for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, primary tumor site metastasis or osseous metastasis cancer, and are expected to be developed into a new generation of CSF-1R inhibitor drugs.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: October 19, 2021
    Assignee: ABBISKO THERAPEUTICS CO., LTD.
    Inventors: Baowei Zhao, Mingming Zhang, Hongping Yu, Shuqun Yang, Zhui Chen, Yaochang Xu
  • Patent number: 11149036
    Abstract: The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: October 19, 2021
    Assignees: MSD R&D (China) Co., Ltd., Merck Sharp & Dohme Corp.
    Inventors: John J. Acton, III, Jianming Bao, Qiaolin Deng, Melissa Egbertson, Ronald Ferguson, II, Xiaolei Gao, Scott Timothy Harrison, Sandra L. Knowles, Chunsing Li, Michael Man-Chu Lo, Robert D. Mazzola, Jr., Zhaoyang Meng, Meng Na, Michael T. Rudd, Oleg Selyutin, David M. Tellers, Ling Tong, Fengqi Zhang
  • Patent number: 11149035
    Abstract: A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoletic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: October 19, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DFVELOPMENT LIMITED
    Inventors: David Norman Deaton, Barry George Shearer, Mark Andrew Youngman
  • Patent number: 11142520
    Abstract: The invention provides compounds of formula (I), stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof: (I) wherein A1 to A6 and R1 to R4 are as defined herein. Such compounds are suitable for use in the treatment or prevention of diseases or conditions which are mediated by the activation of lactate dehydrogenase A (LDHA), for example cancer.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: October 12, 2021
    Assignee: ARCTIC PHARMA AS
    Inventors: Jo Klaveness, Bora Sieng, Steffi Lundvall, Claudia Alejandra Bøen, Kathrin Hnida
  • Patent number: 11124504
    Abstract: Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof: wherein X, Y, R1, R2, R4, R5 R6, R7, R8 and R11 are as defined herein.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: September 21, 2021
    Assignees: THE SCRIPPS RESEARCH INSTITUTE, BLACKTHORN THERAPEUTICS, INC.
    Inventors: Edward Roberts, Miguel A. Guerrero, Mariangela Urbano, Hugh Rosen, Robert M. Jones, Candace Mae Laxamana, Xianrui Zhao, Eric Douglas Turtle
  • Patent number: 11117864
    Abstract: The invention relates to a compound chosen from the compounds of formula (I) below, the optical and geometrical isomers thereof and the tautomers thereof, and also the addition salts thereof with an acid or a base, and the solvates thereof: (I). The invention also relates to the use of these particular compounds and the compositions for dyeing keratin fibers.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: September 14, 2021
    Assignee: L'OREAL
    Inventors: Stéphane Sabelle, Aziz Fadli
  • Patent number: 11103493
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: August 31, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Hua Zhou, Xavier Fradera, Yongxin Han, Meredeth A. McGowan, Nunzio Sciammetta, Catherine White, Wensheng Yu
  • Patent number: 11091497
    Abstract: 1-Phenylacetyl-8-aminohexahydro-2H-pyrano[3,4-b]pyrazines of formula are disclosed. The compounds are kappa ligands and are useful to treat drug dependency, pruritus, pain, and inflammation.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: August 17, 2021
    Assignee: The Rockefeller University
    Inventors: Mary Jeanne Kreek, Amy Ripka, Brian Reed, Eduardo Butelman
  • Patent number: 11091479
    Abstract: The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: August 17, 2021
    Assignee: YUHAN CORPORATION
    Inventors: Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Dong Hoon Kim, Su Bin Choi, Sol Park, Hyun Ho Choi, Tae Wang Kim, Mi Kyeong Ju, Na Ry Ha
  • Patent number: 11078211
    Abstract: Provided are a compound represented by the following formula I; a novel photoreactive compound that can be used in nucleic acid photoreaction techniques by a photoreactive crosslinking agent comprising the compound; and a photoreactive crosslinking agent in which the photoreactive compound is used.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: August 3, 2021
    Assignees: JAPAN ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY, NICCA CHEMICAL CO., LTD.
    Inventors: Takahiro Inatsugi, Ayako Koto, Isao Ishimaru, Masahiko Takamura, Kenzo Fujimoto
  • Patent number: 11078161
    Abstract: Disclosed herein are a compound of formula (I) and a preparation method and uses thereof. The compound shows a good inhibitory activity against ROCK, providing a new medicinal strategy to clinically treat the diseases associated with abnormal ROCK activity.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: August 3, 2021
    Assignee: HITGEN INC.
    Inventors: Jin Li, Dengyou Zhang, Jingchao Feng, Wei Liao, Li Lin, Si Li
  • Patent number: 11078183
    Abstract: The present invention concerns the tetrahydrate form of the compound: (3S)-4-{4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide, dihydrochloride, its process of preparation and therapeutical uses thereof.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 3, 2021
    Assignee: BIOPROJET
    Inventors: Marc Capet, Jeanne-Marie Lecomte, Jean-Charles Schwartz
  • Patent number: 11072596
    Abstract: Disclosed are a compound as shown in general formula I, a pharmaceutically acceptable salt, an isomer or a mixture thereof, and a solvate, a polymorph, a stable isotope derivative or a prodrug thereof. The compound of the present disclosure has comparatively strong PARP inhibitory activity and can be used for treating diseases associated with PARP, such as cancers and inflammatory diseases.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: July 27, 2021
    Assignee: SELECTION BIOSCIENCE LLC
    Inventors: Fuyao Zhang, Hongshun Yuan, Xiaoming Shen
  • Patent number: 11059817
    Abstract: The present technology provides compounds according to Formulas (I), (II), or (III) useful in inhibiting an enterovirus, paramyxovirus, respiratory virus, flaviviridae virus, bunyaviridae virus, togaviridae virus, or rabies virus in a cell and/or treating subjects suffering from an enterovirus, paramyxovirus, respiratory virus, flaviviridae virus, bunyaviridae virus, togaviridae virus, or rabies virus.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: July 13, 2021
    Assignee: The Regents of the University of California
    Inventors: Paul Krogstad, Michael E. Jung, Jun Zuo, Yanpeng Xing
  • Patent number: 11045471
    Abstract: The present invention provides an agent containing an orotic acid derivative that has high solubility in solvent and has superior physiological activity. The agent of the present invention is a melanin production inhibitor, whitening agent, fibroblast activator, collagen and/or elastin production promoter or wrinkle ameliorant containing as an active ingredient thereof an orotic acid derivative represented by the following general formula (1) or a salt thereof. In formula (1), R preferably represents a side chain of glutamic acid, glycine, histidine or aspartic acid. [In formula (1), R represents a side chain of a naturally-occurring amino acid and R may form, together with a nitrogen atom adjacent thereto through a single carbon atom, a hetero ring.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: June 29, 2021
    Assignee: SHOWA DENKO K.K.
    Inventors: Daisuke Yagyu, Yuko Nakagami, Ryota Niibayashi, Eiko Kato
  • Patent number: 11044910
    Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein A, X, Y, Z, R1, R2a, R2b and Q are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: June 29, 2021
    Assignee: FMC Corporation
    Inventor: Caleb William Holyoke, Jr.
  • Patent number: 11045459
    Abstract: The invention provides compositions and methods for intrathecal administration of the compound MCOPPB or a pharmaceutically acceptable salt thereof for treating pain, such as neuropathic pain suffered by an adult human.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: June 29, 2021
    Assignee: Centrexion Therapeutics Corporation
    Inventors: James N. Campbell, Barton Harley Manning
  • Patent number: 11040031
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, and G, are defined herein.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: June 22, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tianbao Lu, Peter J. Connolly, Maxwell David Cummings, Joseph Kent Barbay, Kevin D. Kreutter, Tongfei Wu, Gaston Stanislas Marcella Diels, Jan Willem Thuring, Ulrike Philippar, James Patrick Edwards, Fang Shen
  • Patent number: 11034702
    Abstract: The present disclosure relates to fused N-arylsulfonamidyl-thienoisoquinoline compounds, derivatives and pharmaceutical compositions thereof, and methods and uses in inhibiting cancer cell growth, along with a supplemental anti-cancer agent. Centrosome targeting and microtubule depolymerisation are attractive in designing the present chemotherapeutic compounds. The various diseases and conditions treated include various types of cell cancers, and in vitro inhibition.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: June 15, 2021
    Assignee: VALORBEC, SOCIÉTÉ EN COMMANDITE
    Inventors: Pasquale Forgione, Alisa Julienne Piekny, Dilan Boodhai Jaunky, Fei Chen, Jiang Tian Liu
  • Patent number: 11034658
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: June 15, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, Ronald L. Wolin, Anne M. Fourie, Xiaohua Xue